Cancellation of Patent Claims through Reexamination Insufficient to Mount Collateral Attack on Multimillion-Dollar Jury Verdict

Mar 2, 2020

Reading Time : 2 min

KAIST IP US LLC sued several companies for infringement of U.S. Patent No. 6,885,055 (the “’055 Patent”). At the completion of trial, the jury found that defendants had infringed at least one asserted claim of the ’055 Patent and that none of the asserted claims were invalid. Four months later, one of the defendants filed a request for ex parte reexamination of the ’055 Patent, which was granted by the U.S. Patent and Trademark Office (PTO). On reexamination, the PTO rejected the asserted claims. Given that KAIST had not yet exhausted its appeals of that decision, the PTO’s rejection had not yet been deemed final.

Defendants subsequently moved to stay the post-trial phase of the litigation pending completion of the reexamination. The court denied the motion on the basis that: (1) a stay would prejudice KAIST’s right to rely on a jury verdict it expended substantial resources to obtain; (2) the litigation had reached an advanced stage, in that the case had reached trial and both the jury and court had rendered decisions on the merits; and (3) any simplification to the case would be de minimis because only post-trial motions remained, which the court decided contemporaneously with the motion to stay.

In deciding against a stay, two tactical decisions by defendants were of particular importance to the court. First, defendants waited months until after the jury returned a verdict in favor of KAIST before filing the ex parte reexamination request. Second, defendants asserted unpatentability grounds in that request which were not presented to the jury. In the court’s view, filing a request for reexamination post-trial with new unpatentability grounds amounted to a “manipulat[ion] [of] an administrative process designed to streamline disputes to avoid the need for a jury trial.” The court also characterized defendants’ tactics as “a fourth bite at the apple” because defendants had failed on multiple occasions to obtain institution of inter partes review of the ’055 Patent during the pendency of the litigation. Finally, the court cautioned that the administrative remedies afforded by the Patent Act “should not be used to effect a collateral attack on the verdict of a jury empaneled pursuant to the Seventh Amendment or the judgments of an Article III court.” Indeed, the court noted that if the case were stayed and no final judgment issued, “the issuance of a final reexamination certificate would effect the destruction of this lawsuit.”

Practice Tip: A defendant will face significant obstacles justifying a stay during the post-trial phase of a patent infringement litigation where a jury has rendered a verdict in favor of the plaintiff. Such a stay may be even less palatable to a district court if the basis for seeking the stay is the cancellation of the asserted patent claims via ex parte reexamination on unpatentability grounds not presented to the jury. Thus, accused infringers seeking prompt resolution in a patent infringement dispute should exercise diligence in pursuing multiprong patent challenges.

Kaist IP US LLC v. Samsung Elecs. Co. et al., 2:16-cv-01314-JRG (E.D. Tex. Feb. 13, 2020) (Gilstrap, J.)

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.